PEA

Within the SIRIAM Platform, Palmitoylethanolamide (PEA) is classified as one of the principal Release Core Components.

Unlike the Structural & Dermal Support Core ingredients, which establish the common pharmaceutical architecture, PEA contributes to the functional identity of the Release phase. Its inclusion reflects the SIRIAM concept of creating a transition from a stable structural formulation towards a formulation designed to support physiological adaptation within the neurodermal environment.

PEA is not considered a Regional Signature Component. Instead, it represents a platform-wide functional ingredient that may be incorporated where the Release architecture is intended.

Within the SIRIAM formulation philosophy, PEA contributes to the common Release framework while allowing Regional Signature Components to determine the anatomical specificity of each magistral formulation.

Palmitoylethanolamide (PEA) is an endogenous fatty acid amide belonging to the family of N-acylethanolamines. It is synthesised by numerous mammalian tissues and has been extensively investigated for its role in maintaining cellular homeostasis during physiological stress and inflammatory responses.

Experimental research has demonstrated that PEA interacts with several molecular pathways, including activation of peroxisome proliferator-activated receptor alpha (PPAR-α) and indirect modulation of mast cell activity, glial cell activation and neuroimmune signalling. These mechanisms are believed to contribute to restoration of tissue homeostasis rather than direct pharmacological suppression of inflammation.

A substantial body of human clinical research has evaluated oral PEA supplementation across various chronic pain conditions, including neuropathic pain, musculoskeletal pain and chronic inflammatory disorders. Multiple systematic reviews suggest that oral PEA demonstrates a favourable safety profile and may reduce pain intensity in selected patient populations, although study quality remains variable.

Scientific evidence supporting topical PEA formulations is considerably more limited. Preliminary studies suggest potential local biological activity, but high-quality clinical trials remain scarce.

Current scientific evidence evaluates PEA primarily as an isolated compound or within conventional pharmaceutical formulations. At present, no published studies specifically investigate PEA as part of a region-specific neurodermal formulation system such as the SIRIAM Platform. Consequently, its incorporation reflects the biological plausibility of its mechanisms together with the architectural design philosophy of the platform rather than established evidence for region-specific neurodermal application.

PEA functions as one of the defining functional ingredients of the Release Core.

Its architectural role is to contribute to the common Release formulation shared by multiple SIRIAM preparations while remaining independent of regional anatomical differentiation.

The precise concentration may evolve as pharmaceutical optimisation and clinical evaluation of the platform continue.